The company plans to use the funds to develop and commercialize its lead product, a mass spectrometry-based glycoproteomic blood test for ovarian cancer.
The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.
The company has also achieved a CE-IVD mark for its HemeAccuTest, which targets hematological malignancies.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.
The firm will use the funding to advance commercialization of its RNA disruption assay and continue its breast cancer response therapy trial.
1Drop anticipates the platform will be capable of handling up to 64 clinical biomarkers, including indicators of cardiovascular diseases and many others.
The platform is currently used by pathologists doing research and could be available in a year for primary diagnosis of cancers in clinical settings.
The firm anticipates that in 2019 it will begin clinical trials for a comprehensive metabolic panel for use on its point-of-care platform.
The award comes after DNAe completed the first phase of a contract valued at up to $51.9 million, which BARDA initiated in September 2016.
The company's technology uses a drop of blood applied to a biochip to provide a "complete panel" of diagnostic test results within 15 minutes.